posteditor

posteditor

Partner Therapeutics announces submission of supplemental Biologics License Application (sBLA) to FDA for BIZENGRI® (zenocutuzumab-zbco) in NRG1 Fusion Positive Cholangiocarcinoma and Inclusion in updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

B LEXINGTON, Mass., April 14, 2026 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, announces the submission of a supplemental Biologics… Login to continue reading Login Sign up for complimentary access Sign Up Now Close